Shattuck Labs, Inc. (NASDAQ:STTK) Given Average Recommendation of “Moderate Buy” by Brokerages

Shattuck Labs, Inc. (NASDAQ:STTK) has been assigned a consensus recommendation of “Moderate Buy” from the eight research firms that are covering the company, MarketBeat reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $10.00.

A number of brokerages have weighed in on STTK. Piper Sandler started coverage on shares of Shattuck Labs in a research report on Wednesday, January 28th. They issued an “overweight” rating and a $15.00 price objective for the company. TD Cowen restated a “buy” rating on shares of Shattuck Labs in a research note on Friday. HC Wainwright raised Shattuck Labs from a “neutral” rating to a “buy” rating and set a $6.00 price target for the company in a report on Monday, December 1st. Citigroup increased their price target on Shattuck Labs from $2.00 to $4.00 and gave the stock a “neutral” rating in a research report on Tuesday, January 6th. Finally, Needham & Company LLC initiated coverage on Shattuck Labs in a report on Friday. They issued a “buy” rating and a $25.00 price objective on the stock.

Institutional Investors Weigh In On Shattuck Labs

A number of institutional investors have recently added to or reduced their stakes in the stock. Turtle Creek Wealth Advisors LLC purchased a new stake in Shattuck Labs in the 3rd quarter worth $29,000. Virtu Financial LLC purchased a new position in Shattuck Labs during the third quarter valued at $38,000. Squarepoint Ops LLC acquired a new stake in shares of Shattuck Labs in the third quarter valued at about $46,000. Mallini Complete Financial Planning LLC acquired a new stake in shares of Shattuck Labs in the fourth quarter valued at about $83,000. Finally, Dimensional Fund Advisors LP purchased a new stake in shares of Shattuck Labs during the fourth quarter worth about $85,000. Institutional investors and hedge funds own 58.74% of the company’s stock.

Shattuck Labs Price Performance

NASDAQ:STTK opened at $5.99 on Monday. The company has a 50 day moving average price of $4.17 and a 200-day moving average price of $2.85. Shattuck Labs has a 1-year low of $0.69 and a 1-year high of $6.00. The firm has a market cap of $379.05 million, a price-to-earnings ratio of -7.78 and a beta of 1.55.

Shattuck Labs (NASDAQ:STTK) last announced its quarterly earnings results on Thursday, March 5th. The company reported ($0.12) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.12). The firm had revenue of ($1.00) million for the quarter, compared to analysts’ expectations of $0.17 million. On average, sell-side analysts anticipate that Shattuck Labs will post -1.48 earnings per share for the current fiscal year.

About Shattuck Labs

Shattuck Labs, Inc (NASDAQ: STTK) is a clinical‐stage biotechnology company headquartered in Cambridge, Massachusetts. The company is focused on developing immunotherapeutic vaccines to prevent and treat substance use disorders, with an initial emphasis on opioids. Shattuck Labs employs a proprietary hapten‐carrier conjugate technology designed to generate high‐affinity drug‐specific antibodies that sequester target molecules in the bloodstream and reduce their passage across the blood‐brain barrier.

The company’s lead program targets fentanyl, a synthetic opioid responsible for a significant proportion of overdose fatalities.